Kala Pharmaceuticals (KALA) Misses Q3 EPS by 6c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 5, 2020 7:00 AM EST
-- Obtained FDA Approval for EYSUVISTM, First Prescription Therapy Approved Specifically for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease --
-- EYSUVIS Expected to Begin Shipping to Wholesalers by End of 2020 --
-- 3Q 2020 INVELTYS® Net Revenue of $2.2 Million --
-- Cash Position and INVELTYS Revenue Expected to Provide Runway Into at Least 3Q 2022
EYSUVIS Revenue Expected to Provide Additional Runway --
-- Conference Call and Webcast at 8:00 a.m. ET --
WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (NASDAQ:... More
